Novo Nordisk chief: Inversago Pharma acquisition is "a great addition to our pipeline"
Novo Nordisk announced on Thursday that it is acquiring Canadian biotech company Inversago Pharma in a deal that could total USD 1.075bn if all milestones are met.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk books DKK 24bn operating profit and upgrades
For subscribers